OptiNose said Monday that it has received an undisclosed amount of Series C-1 funding. The company’s investors include Avista Capital Partners, WFD Ventures and Entrepreneurs Fund. Headquartered in Yardley, Penn., OptiNose is a specialty pharmaceutical firm that built around a nasal delivery platform.

from PE Hub Blog http://ift.tt/UWtTlT
via IFTTT

Publicités